BREXIT – Some food for thought

As I write this I am watching the RIO 2016 Olympic games – what a performance by Team GB, Second in the medals table with 61 medals and counting! Quite a contrast to all the negative publicity that the UK has received following the majority vote to leave the EU. The UK has a lot to offer in terms of it’s vast experience in the Pharmaceutical and Biotech industry, and has worked and continues to work, with multiple nations to build on improving the health, general economy and security of all countries involved. So why now should this attitude change significantly post-Brexit if the objective is to improve the quality of life of all the populations involved? This is certainly a time of change

Summary of EC report on use of medicinal products for human use

European Commission report – “Pharmacovigilance related activities of Member States and the European Medicines Agency concerning medicinal products for human use (2012-2014)” The EU Commission has published the above titled report on 8th August 2016 which describes the activities of the EU’s networked and collaborative system for monitoring and controlling the safety of human medicines and is focused on activities since the start of operation of new legislation in 2012 until the end of 2014, but also includes information on some tasks and processes initiated up to July 2015. In summary the report shows: Number and types of information reviewed by Pharmacovigilance Risk Assessment Committee (

© 2020 Reumat Consulting

Website by Otters Pool Studio